Document Detail


Iloprost in pulmonary hypertension.
MedLine Citation:
PMID:  20477231     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Pulmonary hypertension is a clinically relevant, life-threatening disease. Based pathophysiologically on a dysbalance of vasoactive mechanisms, the therapeutic use of vasodilative agents is one of the major treatment options. Prostanoids, such as iloprost, are widely used in the treatment of patients with pulmonary hypertension. With the focus on pulmonary hypertension, this article reviews the most relevant experimental and clinical data for the inhalative and intravenous application of iloprost. To summarize, the available data on iloprost suggest it has a clinical and hemodynamic benefit to patients with pulmonary hypertension.
Authors:
Ralf Ewert; Sven Gläser; Christian Opitz
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of respiratory medicine     Volume:  2     ISSN:  1747-6356     ISO Abbreviation:  Expert Rev Respir Med     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2010-05-18     Completed Date:  2010-07-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278196     Medline TA:  Expert Rev Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  689-702     Citation Subset:  -    
Affiliation:
Division of Pneumology and Infectious Diseases, Ernst Moritz Arndt University, Greifswald, Germany. ewert@uni-greifswald.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  News in brief.
Next Document:  Influenza vaccination of healthcare workers, oseltamivir resistance and prepandemic vaccination.